Extended release Mirapex approved for early Parkinson's in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Boehringer Ingelheim's Mirapex ER (pramipexole hydrochloride) for the once-daily treatment of the signs and symptoms of early idiopathic Parkinson's disease (PD). The prolonged-release oral formulation is already approved for early and advanced PD in the EU, and the immediate-release three times daily formulation has been available for PD in the US since 1997.